Ethambutol: Nursing Drug Guide, Optic Neuropathy & NCLEX Review
Healthcare medication guide: baseline and serial vision surveillance, multidrug tuberculosis regimens, renal dose adjustment, and prompt hold rules when color vision or visual acuity changes.
Ethambutol may cause decreases in visual acuity due to optic neuritis. Toxicity may relate to dose and duration; it is generally reversible when the drug is discontinued promptly, but irreversible blindness has been reported. Test visual acuity before therapy and periodically—monthly when daily dose exceeds 15 mg/kg. Patients who cannot report vision changes (e.g., young children, unconscious patients) are contraindicated unless clinical judgment allows use with alternative monitoring. Never give ethambutol alone; it must be combined with at least one other antituberculosis drug.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm weight-based mg/kg is correct, companion TB drugs are on the MAR, and the patient has no new blurred vision or color discrimination problems. Ethambutol is renally cleared—reduced kidney function increases toxicity risk. Any significant Snellen decline or subjective eye symptom means hold the dose and contact the prescriber the same shift.
Most common brand names
Ethambutol is the generic name for the antimycobacterial agent used in multidrug tuberculosis regimens.
Common U.S. brand: MYAMBUTOL (ethambutol hydrochloride tablets 100 mg and 400 mg). Ethambutol is not typically supplied as a standalone OTC product; it appears in institution-specific tuberculosis combination protocols with agents such as isoniazid and rifampin per susceptibility and local formulary.
Why we give it — Indications
Ethambutol is indicated for pulmonary tuberculosis as part of combination therapy—not as monotherapy.
| Use | Detail |
|---|---|
| Initial tuberculosis treatment | 15 mg/kg (7 mg/lb) once daily with at least one other antituberculous drug (commonly isoniazid with or without other agents per regimen). |
| Retreatment / prior therapy | 25 mg/kg (11 mg/lb) once daily for 60 days, then reduce to 15 mg/kg daily; must add at least one other antituberculous drug to which organisms are susceptible. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ethambutol diffuses into actively growing Mycobacterium cells, including M. tuberculosis, and impairs cell metabolism and multiplication. It is bacteriostatic against tubercle bacilli and helps reduce emergence of resistance when combined with other antituberculosis drugs. Nurses should remember that monotherapy leads to resistance—ethambutol must always be paired with companion drugs on the MAR.
Dosing overview
Dosing is weight-based once every 24 hours. Therapy continues until bacteriological conversion is permanent and maximal clinical improvement has occurred per prescribing information. Verify patient weight and whether the patient is on initial versus retreatment dosing.
Missed dose: If a dose is missed, follow institutional tuberculosis DOT protocol. Do not double the next dose without prescriber or pharmacist guidance. Document missed doses because irregular adherence increases treatment failure and resistance risk.
Before you give it — Safety check
Pretreatment checks
- Confirm tuberculosis regimen includes at least one companion antituberculosis drug—ethambutol is not used alone.
- Baseline visual acuity (Snellen) for each eye separately and both eyes together; ophthalmoscopy and color discrimination assessment per prescriber protocol.
- Review allergies, renal function (serum creatinine, eGFR), hepatic labs, and ability to report vision changes.
Contraindications
- Known hypersensitivity to ethambutol.
- Known optic neuritis unless prescriber determines benefit outweighs risk.
- Patients unable to appreciate and report visual side effects (e.g., young children, unconscious patients) unless clinical judgment permits use with specialized monitoring.
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Aluminum hydroxide antacids | Coadministration reduced mean serum ethambutol concentrations and urinary excretion by approximately 20% and 13% in a labeling study. | Avoid concurrent aluminum-containing antacids for at least 4 hours after ethambutol; document timing on the MAR. |
| Other antituberculosis hepatotoxins | Liver toxicities including fatalities reported; multidrug regimens may confound attribution. | Monitor liver function tests at baseline and periodically; hold and notify for jaundice, severe GI symptoms, or rising transaminases per protocol. |
| Renally cleared drugs / AKI | Ethambutol accumulates when kidney function declines, increasing optic neuropathy risk. | Trend BMP; request pharmacy review for dose interval and serum level monitoring. |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet (ethambutol hydrochloride), once every 24 hours. Absorption is not significantly altered by food per prescribing information.
- Give once daily at the same time when possible to support DOT and adherence.
- May administer with food; absorption not significantly altered per labeling.
- Perform medication reconciliation so ethambutol is not duplicated or given without companion TB drugs.
Ethambutol should not be used alone in initial or retreatment therapy. Verify at least one additional active antituberculosis agent is ordered, available, and tolerated before administering.
Expected therapeutic response
- Improving pulmonary symptoms (e.g., decreasing cough, improving energy) over weeks—TB response is slow; continue vision monitoring throughout.
- Negative or improving acid-fast bacilli / culture data per laboratory protocol (not a nurse-administered endpoint but guides continuation).
- Stable visual acuity and color vision on serial testing when dose and renal function remain appropriate.
Red flags — Stop and act
Optic neuropathy may begin with subjective symptoms before Snellen changes. Progressive visual decline during therapy should be assumed drug-related until evaluated.
- New blurred vision, scotoma, color blindness, or visual field defect—hold ethambutol and notify prescriber urgently
- Unilateral or bilateral vision loss; difficulty with red-green discrimination
- Jaundice, dark urine, severe abdominal pain, or hypersensitivity rash with fever (possible hepatitis or hypersensitivity syndrome)
- Acute joint pain in a patient with rising uric acid (possible gout precipitated by ethambutol per labeling)
- Significant Snellen decline meeting prescribing information thresholds (e.g., 20/20 to 20/30 = 2 lines / 10 points)—hold drug and arrange repeat testing
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Optic neuritis / decreased visual acuity | Serious; dose- and duration-related; may be irreversible | Hold ethambutol immediately; obtain formal vision testing; notify prescriber; document each eye separately |
| GI upset (nausea, vomiting, anorexia, abdominal pain) | Reported in labeling | Supportive care; differentiate from hepatotoxicity or hypersensitivity syndrome |
| Hepatotoxicity / liver injury | Fatalities reported | Hold drug; trend hepatic panel per protocol; escalate for jaundice or rising transaminases |
| Peripheral neuritis (numbness, tingling) | Reported | Neurologic assessment; notify prescriber; rule out other causes |
| Hypersensitivity / rash / anaphylaxis | Reported; hypersensitivity syndrome may involve hepatitis, pneumonitis, nephritis | Stop ethambutol; escalate urgently; do not rechallenge without specialist guidance |
| Elevated uric acid / acute gout | Reported | Monitor symptoms; notify prescriber if joint pain or swelling |
| Hematologic (thrombocytopenia, leukopenia, neutropenia) | Reported | Review CBC trends; hold and notify if clinically significant cytopenias |
On a small screen, swipe or scroll sideways to see the full table.
Specific incidence rates for individual adverse events are not specified in the reviewed FDA prescribing information.
Overdose, toxicity, and antidote
Ethambutol toxicity is most often dose- and duration-related optic neuropathy rather than a single acute ingestion syndrome. The reviewed prescribing information does not list a specific reversal agent.
Management principles
- Antidote: Not specified in the reviewed prescribing information.
- Optic toxicity: Discontinue ethambutol promptly when significant visual change is confirmed; recovery of visual acuity may occur over weeks to months after discontinuation, though irreversible blindness has been reported.
- Supportive care: Hold the drug, monitor vision and organ function, and coordinate with infectious diseases, ophthalmology, and pharmacy per protocol.
Contact local poison control or medical toxicology services for overdose or toxicity guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Ethambutol vs ethionamide—both are antituberculosis drugs with different toxicity profiles; verify drug name on MAR and pharmacy label
- MYAMBUTOL brand vs other white film-coated tablets—use barcode scanning and independent double-check when available
- Weight-based mg/kg dosing—confirm patient weight used for calculation; retreatment 25 mg/kg daily doses differ from initial 15 mg/kg
- Monotherapy error—ethambutol must never be given as the only antituberculosis drug; verify companion agents on the MAR
- Aluminum antacids—separate by at least 4 hours after ethambutol to avoid reduced absorption
- Vision screening documentation—do not administer if baseline Snellen results are missing when required by protocol, especially at doses above 15 mg/kg/day
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | Once daily oral dose; may be given with food per labeling (absorption not significantly altered). |
| DOT | Directly observed therapy is common for tuberculosis regimens—document observer and time. |
| Vision checks | Test each eye separately and both together; patient must wear corrective lenses if used before treatment. |
| Renal dosing | Coordinate with pharmacy for serum level-guided adjustments when creatinine rises during therapy. |
| Hemodialysis | CDC guidance prefers giving antituberculosis drugs after dialysis when DOT is used—follow institutional protocol. |
| Commonly missed | Subjective eye symptoms before Snellen change; antacid timing; retreatment dose still at 25 mg/kg after day 60. |
| Ask pharmacy when | Renal impairment, suspected toxicity, drug interaction with antacids, or need for serum ethambutol level monitoring. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Decreased renal function | Main elimination is renal; accumulation increases optic toxicity risk in chronic kidney disease and acute injury—dose reduction guided by serum ethambutol levels and pharmacy protocol. |
| Pre-existing eye disease | Cataracts, diabetic retinopathy, recurrent eye inflammation, or optic neuritis make vision change harder to interpret—ophthalmology coordination is essential. |
| Retreatment at 25 mg/kg/day | Higher dose requires monthly eye examinations per labeling; after 60 days, dose should decrease to 15 mg/kg if therapy continues. |
| Pregnancy | Pregnancy Category C: no adequate controlled studies in pregnant women; reports of ophthalmic abnormalities in infants born to women on antituberculosis therapy that included ethambutol. Use only if benefit justifies fetal risk—coordinate with obstetrics and infectious diseases. |
| Lactation | Excreted into breast milk per labeling. Use only if expected maternal benefit outweighs potential risk to the infant; LactMed should be consulted for updated breastfeeding guidance. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Visual acuity (Snellen) before therapy, periodically during treatment, and monthly when dose >15 mg/kg/day; test each eye separately and both together.
- Renal function and serum ethambutol levels when kidney function is impaired or changing.
- Baseline and periodic hepatic, hematologic, and uric acid monitoring per multidrug TB protocol; assess for peripheral neuropathy symptoms.
Document
- Weight, calculated mg/kg dose, DOT observer, and companion antituberculosis drugs administered.
- Snellen results each eye, subjective vision symptoms, and ophthalmology referrals.
- Hold events, prescriber notification, and patient teaching on reporting blurred vision immediately.
Patient teaching
- Take ethambutol exactly as directed for the full course—even when you feel better—stopping early causes resistance.
- Report blurred vision, trouble telling red from green, eye pain, or any vision change immediately—do not wait for the next clinic visit.
- Avoid aluminum antacids within 4 hours of your ethambutol dose unless your clinician advises otherwise.
- Tell your care team about all TB medicines and supplements; never add extra doses on your own.
- Attend scheduled eye exams and laboratory appointments; vision changes can be reversible if caught early.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Any new or worsening visual symptom (blurred vision, color change, field defect) or significant Snellen decline.
- Known optic neuritis or prescriber-directed vision hold pending ophthalmology review.
- Suspected hypersensitivity, severe rash, or clinical hepatitis (jaundice, marked transaminase rise per protocol).
- Acute kidney injury or rising creatinine without pharmacy-approved dose adjustment.
- Order is for ethambutol alone without an active companion antituberculosis drug on the MAR.
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ethambutol nursing workflow centers on vision safety in long multidrug tuberculosis courses. Build vision checks into medication passes the same way you would vitals for high-risk infusions.
1. Check-before-you-give protocol
- Right patient, weight, and mg/kg dose (15 vs 25 mg/kg phase).
- Companion TB drug(s) due and not held for toxicity.
- Ask about blurred vision or color changes since last dose; review latest Snellen if available.
- Confirm no aluminum antacid within 4 hours if patient uses GI medications.
2. High-alert and safety badge
Vision-surveillance medicationEthambutol is not an ISMP high-alert drug, but it requires the same disciplined double-checks as high-risk therapy because vision loss can be permanent.
3. Clinical workflow: hold and question rules
- Hold and clarify any missing baseline vision data before starting retreatment dosing.
- After day 60 of 25 mg/kg retreatment, verify order reflects step-down to 15 mg/kg.
- Escalate same shift if patient cannot describe vision changes but caregiver reports new stumbling or inability to see objects.
4. Critical teach-back questions
- “What eye symptoms should you report right away?” Blurred vision, trouble with colors (especially red-green), blind spots, or any vision change.
- “Can you skip doses when you feel better?” No—take the full multidrug regimen as directed; missed doses increase resistance and treatment failure.
5. Care coordination
Infectious diseases / TB clinic: Regimen changes, susceptibility results, and duration of therapy after sputum conversion.
Ophthalmology / pharmacy: Formal vision testing, toxicity evaluation, serum level monitoring, and renal dose adjustment.
🧠 Quick mental checklist
- Is this patient on ethambutol plus at least one other TB drug?
- What is the mg/kg dose and has retreatment passed 60 days at 25 mg/kg?
- Any new blurred vision, color problem, or Snellen decline?
- Is creatinine rising without a pharmacy dose change?
- Did the patient take an aluminum antacid within 4 hours of ethambutol?
Ethambutol NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ethambutol using a tabbed inpatient tuberculosis case (MAR, labs, vitals, nursing notes), then work through priority action, cue recognition, vision/renal trend interpretation, matrix urgency sorting, visual-testing judgment, and cloze management of optic neuropathy—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Ethambutol 1,200 mg PO daily (25 mg/kg) — scheduled 0800 — given
- Isoniazid 300 mg PO daily — given 0800
- Rifampin 600 mg PO daily — given 0800
- Pyrazinamide 1,500 mg PO daily — given 0800 (companion drug on MAR)
- Aluminum hydroxide antacid PRN — held since vision symptoms reported
- Baseline Snellen: R 20/20, L 20/20 (week 0)
- Week 4: R 20/25, L 20/30 — documented; no prescriber notified
- Week 8 (today): patient reports colors look “faded”; formal Snellen pending
- Creatinine: 1.0 → 1.4 → 1.8 mg/dL over 8 weeks; eGFR 48 mL/min/1.73 m²
- ALT 32 → 38 U/L; AST 29 U/L
- 48-year-old with pulmonary tuberculosis, retreatment phase (25 mg/kg)
- Weight 48 kg (unchanged) — calculated dose 1,200 mg/day
- Temp 37.1 °C; HR 88; RR 18; BP 118/72
- SpO₂ 96% on room air
- 0800: Patient states, “Red looks brown and I cannot read messages on my phone.”
- 0815: Prior nurse noted week-4 Snellen change but ethambutol continued
- 0830: Nephrology following rising creatinine; pharmacy consult pending for ethambutol interval
- 0845: Nurse reviewing MAR and lab tabs before administering 0800 dose (already given) and planning escalation
Answer key & rationale
Frequently asked questions
What must nurses check before giving ethambutol?
Confirm multidrug tuberculosis regimen (never ethambutol alone), correct weight-based mg/kg dose, baseline or latest Snellen vision for each eye, renal function, hepatic labs per protocol, and whether the patient has new blurred vision or color discrimination problems. Separate aluminum antacids by at least 4 hours.
When should ethambutol be held?
Hold for significant visual acuity decline, subjective eye symptoms, suspected optic neuritis, inability to monitor vision as required, acute kidney injury without dose adjustment, hypersensitivity or hepatitis per protocol, or orders missing companion antituberculosis drugs. Notify prescriber and pharmacy the same shift.
What adverse effects matter most?
Optic neuritis with decreased visual acuity (including irreversible blindness) is the defining toxicity. Also monitor for hepatotoxicity, peripheral neuritis, hypersensitivity syndrome, hematologic effects, and hyperuricemia with possible acute gout per labeling.
What labs and assessments should be monitored?
Snellen visual acuity before therapy and periodically (monthly when dose exceeds 15 mg/kg/day), each eye separately; renal function and serum ethambutol levels when kidney function is impaired; baseline and periodic hepatic and hematologic labs per multidrug TB protocol.
Is there an antidote for ethambutol overdose?
A specific antidote is not specified in the reviewed FDA prescribing information. Management of toxicity focuses on prompt drug discontinuation when vision changes meet significance thresholds, ophthalmology involvement, and supportive care. Contact local poison control or toxicology services per facility protocol for ingestion concerns.
References
-
U.S. National Library of Medicine. ETHAMBUTOL HYDROCHLORIDE tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6428d6-3745-4337-ad78-ebfff9f49135
-
Drugs and Lactation Database (LactMed). Ethambutol. Bethesda (MD): National Library of Medicine.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM460/
-
Centers for Disease Control and Prevention. Treatment for Drug-Susceptible Tuberculosis Disease.https://www.cdc.gov/tb/hcp/treatment/tuberculosis-disease.html
-
Nahid P, Dorman SE, et al. ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. CDC guideline PDF.https://www.cdc.gov/tb/publications/guidelines/pdf/Clin-Infect-Dis.-2016-Nahid-cid_ciw376.pdf
-
Centers for Disease Control and Prevention. Treatment of Tuberculosis (MMWR Recommendations and Reports 2003).https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.